Marc Lichtenfeld at The Smart Profits Report says he’s found an “immense” investment opportunity in a small-cap biotech firm.

There are three entry points in biotech stocks. They are: The first stages of research for a new drug; the initial human trial phases; and immediately before the drug is FDA approved. The later the entry point, the safer the investment.

The stock Marc has his eye on is a late-stage company. It is finishing Phase III trials for a unique cancer treatment drug which, if successful, will corner an entire market.

Within the first few months of 2008, shares of a billion-dollar biotech ran back and forth between $20 and $30… losing 50% one week only to pick it back up the next.

Some sectors lend themselves beautifully to trend-following techniques. Biotechnology, for example, is a sector that goes through huge booms and busts. The reason is simple: New, world-changing technologies are a sexy story.